<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Irl B Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph I Wolfsdorf, MD, BCh
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also called hyperosmotic hyperglycemic nonketotic state [HHNK]) are two of the most serious acute complications of diabetes. They each represent an extreme in the hyperglycemic spectrum.
        </p>
        <p>
         The epidemiology and the factors responsible for the metabolic abnormalities of DKA and HHS in adults will be discussed here. The clinical features, evaluation, diagnosis, and treatment of these disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) is characteristically associated with type 1 diabetes. It also occurs in type 2 diabetes under conditions of extreme stress such as serious infection, trauma, cardiovascular or other emergencies, and, less often, as a presenting manifestation of type 2 diabetes, a disorder called ketosis-prone diabetes mellitus. (See
         <a class="medical medical_review" href="/z/d/html/1775.html" rel="external">
          "Syndromes of ketosis-prone diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         COVID-19 infection has also been associated with greater risks of DKA in both type 1 and type 2 diabetes. (See
         <a class="medical medical_review" href="/z/d/html/128127.html" rel="external">
          "COVID-19: Issues related to diabetes mellitus in adults", section on 'Clinical presentations'
         </a>
         .)
        </p>
        <p>
         DKA is more common in young (&lt;65 years) patients, whereas hyperosmolar hyperglycemic state (HHS) most commonly develops in individuals older than 65 years [
         <a href="#rid1">
          1,2
         </a>
         ]. According to the Diabetes Surveillance System of the Centers for Disease Control and Prevention (CDC), overall, age-adjusted DKA hospitalization rates decreased slightly from 2000 to 2009, then reversed direction, steadily increasing from 2009 to 2014 at an average annual rate of 6.3 percent. In-hospital case-fatality rates declined consistently during the study period from 1.1 to 0.4 percent  (
         <a class="graphic graphic_figure graphicRef117707" href="/z/d/graphic/117707.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Population-based data are not available for HHS. The rate of hospital admissions for HHS is lower than the rate for DKA and accounts for less than 1 percent of all primary diabetic admissions [
         <a href="#rid1">
          1,4-6
         </a>
         ]. The mortality rate for patients with HHS is between 10 and 20 percent, which is approximately 10 times higher than that for DKA [
         <a href="#rid7">
          7
         </a>
         ]. The mortality rate for hyperglycemic crisis declined between 1980 and 2009 [
         <a href="#rid8">
          8
         </a>
         ]. Mortality in hyperglycemic crisis is primarily due to the underlying precipitating illness and only rarely to the metabolic complications of hyperglycemia or ketoacidosis [
         <a href="#rid1">
          1,9
         </a>
         ]. The prognosis of hyperglycemic crisis is substantially worse at the extremes of age and in the presence of coma and hypotension [
         <a href="#rid9">
          9-12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H1221555">
         <span class="h2">
          Normal response to hyperglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hormonal regulation of glucose homeostasis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1785.html" rel="external">
          "Pancreatic beta cell function"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1789.html" rel="external">
          "Insulin action"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">
          "Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Summarized briefly, the extracellular concentration of glucose is primarily regulated by two hormones: insulin and glucagon. As the serum glucose concentration rises after a glucose meal, glucose enters the pancreatic beta cells, initiating a sequence of events leading to insulin release.
        </p>
        <p>
         Insulin restores normoglycemia by diminishing hepatic glucose production via reductions in both glycogenolysis and gluconeogenesis and by increasing glucose uptake by skeletal muscle and adipose tissue. Insulin-induced inhibition of glucagon secretion contributes to the decline in hepatic glucose production; this effect is mediated by direct inhibition of glucagon secretion and of the glucagon gene in the pancreatic alpha cells [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1221319">
         <span class="h2">
          Spectrum of metabolic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two hormonal abnormalities are largely responsible for the development of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) in patients with uncontrolled diabetes [
         <a href="#rid13">
          13,14,16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin deficiency and/or resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucagon excess, which may result from removal of the normal suppressive effect of insulin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although glucagon excess contributes to the development of DKA, it is not essential. As an example, patients with complete pancreatectomies and who have no pancreatic glucagon will develop DKA if insulin is withheld; however, it takes longer for DKA to develop compared with patients with type 1 diabetes [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to these primary factors, increased secretion of catecholamines, cortisol, and growth hormone, which oppose the actions of insulin, also contribute to the increases in glucose and ketoacid production  (
         <a class="graphic graphic_algorithm graphicRef78145" href="/z/d/graphic/78145.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The deficiency in insulin (either absolute deficiency, or a relative deficiency caused by excess counterregulatory hormones) is more severe in DKA compared with HHS. Since suppression of lipolysis and ketogenesis is more sensitive to insulin than the inhibition of gluconeogenesis, the residual insulin secretion and its systemic activity in HHS is sufficient to minimize the development of ketoacidosis but not adequate to control hyperglycemia [
         <a href="#rid1">
          1
         </a>
         ]. The increase in glucagon levels and activity is also less in HHS generating a smaller decrease in the insulin/glucagon ratio, which generates a lesser stimulus to ketogenesis [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         In patients with absolute or relative insulin deficiency, DKA and HHS are usually precipitated by stresses that act in part by increasing the secretion of glucagon, catecholamines, and cortisol  (
         <a class="graphic graphic_table graphicRef64374" href="/z/d/graphic/64374.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Precipitating factors'
         </a>
         .)
        </p>
        <p>
         DKA and HHS are two extremes in the spectrum of hyperglycemic crisis, and patients can present anywhere along the continuum of diabetic metabolic derangement  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Hyperglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum glucose concentration in HHS frequently exceeds 1000 mg/dL (56 mmol/L), but in DKA, it is generally below 800 mg/dL (44 mmol/L) and often in the 350 to 450 mg/dL (19.4 to 27.8 mmol/L) range [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Laboratory findings'
         </a>
         .)
        </p>
        <p>
         At least two factors contribute to less severe hyperglycemia in DKA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with DKA often present earlier in the course of their acute disease with symptoms of ketoacidosis (such as shortness of breath, abdominal pain, and nausea and vomiting), rather than late with symptoms due to hyperosmolality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with DKA tend to be younger and to have a higher glomerular filtration rate. During the first several years of diabetes, patients may have a supranormal glomerular filtration rate, with levels as great as 50 percent above predicted. As a result, patients with DKA generally have a much greater capacity to excrete glucose than the usually older patients with HHS. This severe degree of glucosuria limits the severity of the hyperglycemia. (See
         <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">
          "Diabetic kidney disease: Pathogenesis and epidemiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the glucosuria associated with DKA (and HHS) initially minimizes the rise in serum glucose, the osmotic diuresis caused by glucosuria usually leads to volume depletion and a reduction in glomerular filtration rate that limits further glucose excretion [
         <a href="#rid18">
          18-21
         </a>
         ]. This effect is more pronounced in HHS, which results in a higher serum glucose than seen in DKA.
        </p>
        <p>
        </p>
        <p>
         Hormonal alterations in DKA and HHS generate hyperglycemia by their impact on three fundamental processes in glucose metabolism  (
         <a class="graphic graphic_algorithm graphicRef78145" href="/z/d/graphic/78145.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,22,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired glucose utilization in peripheral tissues
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased hepatic and renal gluconeogenesis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased glycogenolysis
        </p>
        <p>
        </p>
        <p>
         Insulin deficiency and/or resistance in diabetic patients impair peripheral glucose utilization in skeletal muscle. However, decreased glucose utilization alone will produce only postprandial hyperglycemia; glycogenolysis and increased gluconeogenesis are also required for development of the often severe fasting hyperglycemia which occurs in DKA and HHS.
        </p>
        <p>
         Insulin deficiency and/or resistance promote and accelerate hepatic gluconeogenesis for several reasons [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p>
         Insulin deficiency and/or resistance:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase the delivery of gluconeogenic precursors (glycerol from fat and alanine and other amino acids from muscle) to the liver
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activate multiple enzymes in the gluconeogenic metabolic pathway
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase glucagon levels by removing the inhibitory effect of insulin on both glucagon synthesis and secretion
        </p>
        <p>
        </p>
        <p>
         Oxidation of fatty acids, which are delivered in large amounts to the liver due to lipolysis of fat stores, provides the metabolic energy required to drive gluconeogenesis [
         <a href="#rid16">
          16,24,25
         </a>
         ].
        </p>
        <p>
         The importance of glucagon in the development of hyperglycemia and ketoacidosis in uncontrolled diabetes has been demonstrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After discontinuing insulin in a patient with type 1 diabetes, the rate of rise in serum glucose can be markedly attenuated if glucagon release is prevented by infusing somatostatin [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The magnitude of this effect is illustrated by studies in patients who have undergone total pancreatectomy who make neither insulin nor glucagon. In one report, four such patients and six with type 1 diabetes were fasted after having been maintained on intravenous insulin for 24 hours [
         <a href="#rid17">
          17
         </a>
         ]. After withdrawal of insulin, there was a sharp increase in serum glucagon in the patients with type 1 diabetes. Compared with the pancreatectomized patients, these patients had significantly greater increases in blood glucose (225 versus 139 mg/dL [12.5 versus 7.7 mmol/L]) and blood ketone concentration (4.1 versus 1.8 mmol/L) at 12 hours. (See
         <a class="local">
          'Ketone production'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Ketone production
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both insulin deficiency and glucagon excess contribute to the genesis of DKA [
         <a href="#rid17">
          17,24,26
         </a>
         ]. As noted above, however, glucagon is contributory, but not essential, for DKA to occur. Insulin deficiency and resistance (eg, due to high catecholamine levels) will cause enhanced lipolysis from peripheral fat stores, largely related to increased activity of hormone sensitive lipase, which releases free fatty acids and glycerol. The fatty acids are transported, mainly bound to albumin, to the splanchnic bed and are taken up by hepatocytes. Within the hepatocyte cytoplasm, they are "activated" by linkage of the fatty acid to coenzyme A (CoA), forming acyl-CoA (ie, fatty acid-CoA). The combination of low insulin and increased glucagon activity in the liver cells creates conditions that accelerate the entry of the acyl-CoA into the mitochondria. This transport is mediated by a pair of carnitine palmityl transferase reactions [
         <a href="#rid16">
          16,24,26-30
         </a>
         ].
        </p>
        <p>
         Within the mitochondria, beta-oxidation splits the fatty acids into multiple two-carbon units of acetyl-CoA. This molecule can have one of three fates:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enter the Krebs cycle to be oxidized to carbon dioxide (CO
         <sub>
          2
         </sub>
         ) and water (H
         <sub>
          2
         </sub>
         O), thereby creating adenosine triphosphate (ATP)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be indirectly exported into the cytoplasm where the acetyl-CoA is used to synthesize fatty acids
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enter the ketogenic metabolic path to form acetoacetic acid
        </p>
        <p>
        </p>
        <p>
         When fatty acid delivery to the mitochondria is high, then beta-oxidation of the fatty acid usually occurs in a hormonal milieu characterized by low insulin and high glucagon activity. Under these conditions, entry of acetyl-CoA into the Krebs cycle becomes rate limiting, and acetyl-CoA instead is converted to acetoacetic acid. This true ketoacid is the first "ketone body" which forms. The acetoacetic acid may then be reduced to beta-hydroxybutyric acid, which is also an organic acid, or nonenzymatically decarboxylated to acetone, which is not an acid [
         <a href="#rid31">
          31
         </a>
         ]. Ketones provide an alternate water-soluble source of energy when glucose availability is reduced.
        </p>
        <p>
         The factors responsible for the general absence of ketogenesis in HHS are incompletely understood. However, one important issue is the differential sensitivity of fat metabolism and glucose metabolism to the effects of insulin. Studies in humans have demonstrated that the concentration of insulin required to suppress lipolysis is only one-tenth that required to promote glucose utilization [
         <a href="#rid32">
          32
         </a>
         ]. Thus, less severe insulin deficiency, as occurs in HHS compared with DKA, might be associated with sufficient insulin activity to minimize lipolysis (and therefore ketoacid formation) but not enough to block gluconeogenesis, promote glucose utilization, and thereby prevent the development of hyperglycemia [
         <a href="#rid33">
          33
         </a>
         ]. Less marked elevation of glucagon levels and therefore a higher insulin/glucagon ratio also minimizes ketogenesis [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         There are several observations compatible with this general hypothesis. DKA tends to occur in patients with type 1 diabetes, who produce little or no insulin. HHS, in comparison, is found primarily in older patients with type 2 diabetes, who have decreased, but not absent, insulin effect [
         <a href="#rid16">
          16,23,34
         </a>
         ]. However, this distinction is not absolute, since DKA can occur in patients with type 2 diabetes (see
         <a class="medical medical_review" href="/z/d/html/1775.html" rel="external">
          "Syndromes of ketosis-prone diabetes mellitus"
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4633831">
         <span class="h3">
          Anion gap metabolic acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DKA typically presents as an elevated anion gap metabolic acidosis. This is caused by the production and accumulation of beta-hydroxybutyric and acetoacetic acids. The anion gap is calculated by subtracting the serum concentrations of chloride and bicarbonate from the concentration of sodium [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p>
           Serum anion gap = serum sodium - (serum chloride + bicarbonate)
          </p>
         </div>
        </div>
        <p>
         By convention, the measured (reported) sodium concentration (not the sodium concentration corrected for hyperglycemia) should be used for the calculation of the anion gap.
        </p>
        <p>
         The severity of the metabolic acidosis and the increase of the anion gap are dependent upon a number of factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate and duration of ketoacid production
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of metabolism of the ketoacids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of loss of ketoacid anions in the urine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The volume of distribution of the ketoacid anions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of renal net acid excretion
        </p>
        <p>
        </p>
        <p>
         The rate of ketoacid anion excretion depends upon the patient's volume status, renal function, and the degree to which glomerular filtration is maintained. Patients with relatively preserved extracellular fluid (ECF) volume and higher renal function can excrete large quantities of ketoacids (as much as 30 percent of the ketoacid load), and thereby minimize the elevation in anion gap [
         <a href="#rid36">
          36
         </a>
         ]. The magnitude of this effect was illustrated in a study of patients with DKA; ketone production averaged 51 mEq/hour, while net acid excretion with the ketoacid anions averaged 15 mEq/hour or 30 percent of the ketoacid load [
         <a href="#rid37">
          37
         </a>
         ]. The conversion of acetoacetic acid to acetone can neutralize another 15 to 25 percent of the acid load [
         <a href="#rid37">
          37,38
         </a>
         ]. Rarely, patients excrete ketoacids so efficiently that they present with only a small, or no, elevation in serum anion gap (they have a pure non-gap, or hyperchloremic, metabolic acidosis) [
         <a href="#rid36">
          36,39-41
         </a>
         ].
        </p>
        <p>
         Renal excretion of ketoacid anions increases when patients are treated with intravenous isotonic fluids to correct the hypovolemia. Excretion of ketoacid anions reduces the anion gap, but to the extent that they are excreted as sodium and potassium salts, the severity of the systemic acidemia is unchanged [
         <a href="#rid36">
          36,39,42,43
         </a>
         ]. Sodium or potassium ketoanion salts represent both "decomposed" bicarbonate and also "potential bicarbonate." When the ketoacids are generated, the protons mainly combine with bicarbonate to form CO
         <sub>
          2
         </sub>
         . Thus, in essence, bicarbonate anions in the serum are replaced with ketoacid anions ("decomposed bicarbonate"). If the ketoacids are metabolized, then a bicarbonate anion is regenerated ("potential bicarbonate"). Therefore, the urinary loss of ketoacid anions as sodium or potassium salts represents the loss of "potential bicarbonate." Furthermore, excretion of beta-hydroxybutyrate and acetoacetate as sodium and potassium salts will reduce the anion gap and convert the anion gap acidosis to a hyperchloremic, or non-gap, acidosis. Thus, almost all patients with DKA who have relatively intact renal function will develop some degree of hyperchloremic (normal anion gap) metabolic acidosis when they are treated with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and insulin, due to the urinary loss of potential bicarbonate. These principles are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2292.html" rel="external">
          "The delta anion gap/delta HCO3 ratio in patients with a high anion gap metabolic acidosis", section on 'The delta AG/delta HCO3 in ketoacidosis'
         </a>
         .)
        </p>
        <p>
         Studies have demonstrated that a portion of the anion gap acidosis in most patients with DKA is due to yet another organic acid: D-lactic acid. A small, but clinically significant, fraction of ketoacids, acetone, and dihydroxyacetone phosphate (a product of glycolysis) can each be converted to D-lactic acid [
         <a href="#rid44">
          44
         </a>
         ]. D-lactic acid can account for as much as 8 to 10 mEq/L of the anion gap elevation and bicarbonate reduction in patients with severe DKA [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2292.html" rel="external">
          "The delta anion gap/delta HCO3 ratio in patients with a high anion gap metabolic acidosis", section on 'D-lactic acidosis and toluene inhalation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4634824">
         <span class="h3">
          Plasma osmolality and sodium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma osmolality is always elevated in patients with HHS but less so with DKA  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 2
         </a>
         ). The increase in plasma osmolality created by hyperglycemia pulls water out of the cells, expands the ECF, and thereby reduces the plasma sodium (Na) concentration. If a patient with normal serum electrolytes (Na = 140 mEq/L) rapidly developed a glucose concentration of 1000 mg/100 mL and no urine was made, then that patient's serum sodium concentration would fall to value between 119 and 126 mEq/L and the osmolality would increase to a level between 294 and 308 mosmol/L. However, the osmolality usually increases to a greater degree because a large volume of relatively electrolyte-deficient urine is excreted during the evolution of the hyperglycemic state. The loss of this electrolyte-free water further raises the osmolality [
         <a href="#rid18">
          18
         </a>
         ]. In patients with ketoacidosis, high plasma acetone levels also contribute to the elevated osmolality.
        </p>
        <p>
         The measured serum sodium concentration in uncontrolled diabetes mellitus is affected by the interaction of multiple factors, some that lower and others that raise it:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperglycemia raises the ECF osmolality (and tonicity) and shifts water from the intracellular fluid (ICF) space to the ECF space. Expansion of the ECF dilutes serum sodium and reduces its concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucosuria generates an osmotic diuresis which causes the excretion of sodium and potassium salts, and water. The sum of the concentrations of sodium and potassium salts in the urine is generally much lower than the sodium concentration in blood. This indicates that electrolyte-free water is being excreted in the urine. Loss of electrolyte-free water will raise the serum sodium concentration and plasma osmolality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The variable intake of water and the loss of free water in vomitus or nasogastric suction will also impact the serum sodium concentration and plasma osmolality.
        </p>
        <p>
        </p>
        <p>
         Physiologic calculations suggest that, in the absence of urine losses, the serum sodium concentration should fall by approximately 1.6 mEq/L for each 100 mg/100 mL (5.5 mmol/L) increase in glucose concentration [
         <a href="#rid45">
          45
         </a>
         ]. However, when hyperglycemia was induced in six healthy subjects by the administration of somatostatin (to block endogenous insulin secretion) and the infusion of hypertonic dextrose solution, the relationship between the fall in sodium concentration and the increase in glucose concentration was not linear and the reduction in sodium was greater than had been previously reported [
         <a href="#rid46">
          46
         </a>
         ]. These authors suggested that the sodium should fall by approximately 2.4 mEq/L for each 100 mg/100 mL (5.5 mmol/L) increase in glucose concentration. A number of prior and subsequent studies reported a fall in sodium between 1.6 and 2.4 mEq/L for each 100 mg/100 mL increase in glucose [
         <a href="#rid47">
          47
         </a>
         ]. It must be emphasized that these ratios are only very approximate estimates of potential water deficits (or less commonly, excess). However, they do provide a rough estimate of how much the serum sodium concentration will rise as the hyperglycemia is corrected. Because there is so much variation in the literature and so many variables affect this relationship, we recommend the use of a simple ratio of a 2 mEq/L decline in sodium for each 100 mg/100 mL (5.5 mmol/L) increase in glucose concentration above the normal range.
        </p>
        <p class="headingAnchor" id="H3175204">
         <span class="h3">
          Potassium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients presenting with DKA or HHS have a potassium deficit that averages 300 to 600 mEq  (
         <a class="graphic graphic_table graphicRef76060" href="/z/d/graphic/76060.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid48">
          48-50
         </a>
         ]. A number of factors contribute to this deficit, particularly increased urinary losses due both to the glucose osmotic diuresis and the excretion of potassium ketoacid anion salts (the ketoacid anions are filtered primarily as sodium salts, but some of the sodium is reabsorbed in the distal renal tubule in exchange for potassium as a result of volume contraction-related secondary hyperaldosteronism). Gastrointestinal losses and the loss of potassium from the cells due to glycogenolysis and proteolysis also may play a contributory role.
        </p>
        <p>
         Despite these large total body potassium deficits, the serum potassium concentration is usually normal or, in one-third of patients, elevated on admission [
         <a href="#rid18">
          18,48,51
         </a>
         ]. This is mainly due to hyperosmolality and insulin deficiency [
         <a href="#rid22">
          22,48,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">
          "Causes and evaluation of hyperkalemia in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rise in plasma osmolality causes osmotic water movement out of the cells. Potassium also moves into the ECF as a result of at least two mechanisms [
         <a href="#rid45">
          45
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The contraction of the ICF space increases intracellular potassium concentration and favors passive potassium exit through potassium channels in the cell membrane
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The frictional forces between solvent (water) and solute result in potassium being carried across the cell membrane with water (this process is called solvent drag)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin normally promotes potassium uptake by the cells. Therefore, insulin deficiency contributes to elevated serum potassium levels.
        </p>
        <p>
        </p>
        <p>
         Acidemia per se plays a small role in the shift of potassium from the ICF to the ECF in patients with DKA. Although a transcellular exchange of potassium with hydrogen ions does increase serum potassium in some forms of "inorganic" metabolic acidosis [
         <a href="#rid53">
          53
         </a>
         ], it is less important in organic metabolic acidoses such as ketoacidosis or lactic acidosis [
         <a href="#rid48">
          48,53-55
         </a>
         ]. The important role of hyperosmolality and insulin deficiency is illustrated by the observation that hyperkalemia also often occurs in HHS, despite the absence of acidosis [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2353.html" rel="external">
          "Potassium balance in acid-base disorders", section on 'Metabolic acidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1220847">
         <span class="h2">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperglycemic crises are proinflammatory states that lead to generation of reactive oxygen species and oxidative stress. Studies have shown elevated proinflammatory cytokines including tumor necrosis factor-alpha and interleukin (IL)-1B, IL-6, and IL-8. Lipid peroxidation markers, as well as plasminogen activator inhibitor-1 and C-reactive protein (CRP), are also increased [
         <a href="#rid56">
          56
         </a>
         ]. Proinflammatory factors returned to near-normal levels within 24 hours of insulin therapy and resolution of hyperglycemia. The proinflammatory state in DKA results in in vivo activation of T-lymphocytes with de novo emergence of growth factor receptors [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         A variety of eicosanoids, including prostaglandins, are involved in the pathogenesis of diabetes mellitus and its complications [
         <a href="#rid58">
          58
         </a>
         ]. Some are protective and others accelerate organ dysfunction, including pancreatic beta-cell destruction. Prostaglandins accumulate during DKA, increase in the circulation before elevation of epinephrine, and return promptly to normal levels with insulin therapy [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2658640505">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113400.html" rel="external">
          "Society guideline links: Hyperglycemic emergencies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10564610">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83155.html" rel="external">
          "Patient education: Hyperosmolar hyperglycemic state (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Diabetic ketoacidosis (DKA) is more common in younger patients with type 1 diabetes, though it can occur in type 2 diabetes. HHS occurs less frequently and is associated with higher mortality, at least in part due to underlying comorbidity. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolic abnormalities
         </strong>
         – DKA and hyperosmolar hyperglycemic state (HHS) are part of a spectrum, representing the metabolic consequences of insulin deficiency, glucagon excess, and counterregulatory hormonal responses to stressful triggers in patients with diabetes  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Spectrum of metabolic abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hyperglycemia
         </strong>
         – Glucose concentrations are typically lower (usually &lt;800 mg/dL [44 mmol/L]) in DKA compared with HHS (usually &gt;1000 mg/dL [56 mmol/L]). Patients with DKA present earlier because of symptoms and generally can excrete glucose more effectively than older patients with HHS. (See
         <a class="local">
          'Hyperglycemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hyperglycemia results from impaired glucose utilization, increased gluconeogenesis, and increased glycogenolysis  (
         <a class="graphic graphic_algorithm graphicRef78145" href="/z/d/graphic/78145.html" rel="external">
          algorithm 1
         </a>
         ). Gluconeogenesis results from delivery of precursors to the liver from breakdown of fat and muscle and is promoted by insulin deficiency and glucagon excess. Glycogenolysis is stimulated by catecholamines and a high glucagon-to-insulin ratio. Osmotic diuresis further contributes to elevated blood glucose. (See
         <a class="local">
          'Hyperglycemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ketone production
         </strong>
         – Ketoacidosis results from lipolysis, with synthesis of ketones from free fatty acids in the liver mitochondria. Insulin levels in HHS are insufficient to allow appropriate glucose utilization but are adequate to prevent lipolysis and subsequent ketogenesis. (See
         <a class="local">
          'Ketone production'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolic acidosis
         </strong>
         – The elevated anion gap metabolic acidosis characteristic of DKA is caused by the production and accumulation of beta-hydroxybutyric and acetoacetic acids. The severity of the metabolic acidosis is dependent upon a number of factors, including the rate and duration of ketoacid production, the rate of metabolism of the ketoacids, and the rate of acid excretion in the urine. (See
         <a class="local">
          'Anion gap metabolic acidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Plasma osmolality and serum sodium
         </strong>
         – Plasma osmolality is always elevated in patients with HHS but less so with DKA  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 2
         </a>
         ). The marked hyperosmolality seen in HHS is only in part due to the rise in serum glucose. It is also due to the glucose osmotic diuresis that causes urine electrolyte-free water loss. These factors also influence the measured serum sodium concentration, which is variable because of the interaction of multiple factors, some that lower and others that raise it. (See
         <a class="local">
          'Plasma osmolality and sodium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2325623934">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Abbas Kitabchi, PhD, MD, FACP, MACE, now deceased, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention, Diabetes Public Health Resource http://www.cdc.gov/diabetes/statistics/hospitalization_national.htm (Accessed on March 26, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoit SR, Zhang Y, Geiss LS, et al. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2018; 67:362.
          </a>
         </li>
         <li class="breakAll">
          Fishbein HA, Palumbo PJ. Acute metabolic complications in diabetes. In: Diabetes in America, 2nd ed, National Diabetes Data Group, National Institutes of Health, Bethesda, MD  Vol (NIH publ. no: 95-1468), p.283.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157:669.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Joslin's Diabetes Mellitus, 13th, Kahn CR, Weir GC (Eds), Lea &amp; Febiger, Philadelphia 1994. p.738.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care 2014; 37:3124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care 2006; 29:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am 2004; 88:1063.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Umpierrez GE, Murphy MB. Diabetic ketoacidosis and hyperglycemic hypersmolar state. In: International Textbook of Diabetes Mellitus, 3rd, DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley &amp; Sons, Chichester, UK 2004. p.1101.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIsaac RJ, Lee LY, McNeil KJ, et al. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J 2002; 32:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 1981; 304:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamond MP, Hallarman L, Starick-Zych K, et al. Suppression of counterregulatory hormone response to hypoglycemia by insulin per se. J Clin Endocrinol Metab 1991; 72:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A 1991; 88:7224.
          </a>
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders, 5th, McGraw-Hill, New York 2001. p.794.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes AJ, Bloom SR, Goerge K, et al. Ketoacidosis in pancreatectomized man. N Engl J Med 1977; 296:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995; 79:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillman K. Fluid resuscitation in diabetic emergencies--a reappraisal. Intensive Care Med 1987; 13:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000; 29:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Matzuda M, Barret E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chupin M, Charbonnel B, Chupin F. C-peptide blood levels in keto-acidosis and in hyperosmolar non-ketotic diabetic coma. Acta Diabetol Lat 1981; 18:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster DW. Banting lecture 1984. From glycogen to ketones--and back. Diabetes 1984; 33:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saccà L, Orofino G, Petrone A, Vigorito C. Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance. J Clin Invest 1984; 73:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest 1983; 71:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev 1989; 5:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook GA, Nielsen RC, Hawkins RA, et al. Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem 1977; 252:4421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGarry JD, Robles-Valdes C, Foster DW. Role of carnitine in hepatic ketogenesis. Proc Natl Acad Sci U S A 1975; 72:4385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edgerton DS, Ramnanan CJ, Grueter CA, et al. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 2009; 58:2766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen OE, Trapp VE, Skutches CL, et al. Acetone metabolism during diabetic ketoacidosis. Diabetes 1982; 31:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ZIERLER KL, RABINOWITZ D. EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE. J Clin Invest 1964; 43:950.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM, New York 1981. p.95.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khardori R, Soler NG. Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review. Am J Med 1984; 77:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulop M. The treatment of severely uncontrolled diabetes mellitus. Adv Intern Med 1984; 29:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978; 89:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. Nephron 1990; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viallon A, Zeni F, Lafond P, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med 1999; 27:2690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latif KA, Freire AX, Kitabchi AE, et al. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 2002; 25:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu J, Zello GA, Randell E, et al. Closing the anion gap: contribution of D-lactate to diabetic ketoacidosis. Clin Chim Acta 2011; 412:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz MA. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. N Engl J Med 1973; 289:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.
          </a>
         </li>
         <li class="breakAll">
          Emmett M. Case 6: Diabetes and Acidosis. In: NephSAP: Nephrology Self-Assessment Program: Fluid, Electrolyte, and Acid-Base Disturbances, Sterns RH, Emmett M (Eds), The American Society of Nephrology 2013. Vol 12, No 3, p.191.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978; 88:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Murphy MB. Consequences of insulin deficiency. In: Atlas of Diabetes, 4th, Skyler J (Ed), Springer US, New York 2012. p.39.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Chap Z, Ishida T, Field JB. Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 1985; 75:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 2004; 315:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo P, Wang MH. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat 2011; 95:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McRae JR, Day RP, Metz SA, et al. Prostaglandin E2 metabolite levels during diabetic ketoacidosis. Diabetes 1985; 34:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Huang M, Shen X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. J Diabetes Complications 2014; 28:662.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1794 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564476" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hyperglycemic crises in adult patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564476" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hyperglycemic crises in adult patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596400" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596400" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9080921" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hyperglycemic crises in urban blacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9080921" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hyperglycemic crises in urban blacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25342831" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16936146" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308390" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute hyperglycemic crisis in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308390" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute hyperglycemic crisis in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3611564" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prognostic factors in the diabetic hyperosmolar state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12162394" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7015132" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Glucagon and the A cell: physiology and pathophysiology (first two parts).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2026760" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Suppression of counterregulatory hormone response to hypoglycemia by insulin per se.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1651499" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1651499" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/404553" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ketoacidosis in pancreatectomized man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5013637" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7808094" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nonketotic hypertonicity in diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3104431" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fluid resuscitation in diabetic emergencies--a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11149157" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6787828" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : C-peptide blood levels in keto-acidosis and in hyperosmolar non-ketotic diabetic coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6094292" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Banting lecture 1984. From glycogen to ketones--and back.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6373828" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6134753" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2656156" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/863933" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1060116" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Role of carnitine in hepatic ketogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755527" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6818074" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acetone metabolism during diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14169524" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14169524" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6496545" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/401925" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical use of the anion gap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6434787" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6785133" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Renal function and effects of partial rehydration during diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6424416" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The treatment of severely uncontrolled diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6815530" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Plasma acid-base patterns in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/102229" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Hyperchloremic acidosis during the recovery phase of diabetic ketosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2104963" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10628611" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Does bicarbonate therapy improve the management of severe diabetic ketoacidosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12401775" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The use of alkali therapy in severe diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21036159" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Closing the anion gap: contribution of D-lactate to diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4763428" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10225241" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hyponatremia: evaluating the correction factor for hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10225241" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hyponatremia: evaluating the correction factor for hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3084904" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Determinants of plasma potassium levels in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/417652" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5952215" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Diabetic acidosis with initial hypokalemia. Therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16694129" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16694129" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7025622" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Changes in plasma potassium concentration during acute acid-base disturbances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34793" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Serum potassium in lactic acidosis and ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3884666" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15277389" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14766222" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21757024" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Eicosanoids,β-cell function, and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3926565" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prostaglandin E2 metabolite levels during diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25044235" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
